Physician profile
Trisha Mayorga
NPI 1871219741
$5,655.06
in general payments reported to CMS, 2019-2025
25 companies · $1,153 in 2025
The $1,153 reported for 2025 was more than what 83% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $106 · 2023: $3,484 · 2024: $912 · 2025: $1,153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,549.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,549.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $785.17 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $583.42 | 2022-2024 | Aristada, Lybalvi, Aristada Initio |
| Lundbeck LLC | $537.36 | 2022-2025 | Abilify Maintena, Rexulti |
| Abbvie INC. | $452.70 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $413.62 | 2023-2025 | Uzedy, Austedo, Austedo Xr |
| Axsome Therapeutics, INC. | $386.24 | 2023-2025 | Auvelity, Sunosi |
| Corium, LLC | $300.26 | 2023-2025 | Azstarys, Adlarity |
| Takeda Pharmaceuticals U.S.A., INC. | $291.82 | 2022-2024 | Trintellix |
| Ironshore Pharmaceuticals INC. | $233.33 | 2023-2024 | Jornay Pm |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $213.43 | 2023-2025 | Caplyta |
| Bausch Health US, LLC | $186.42 | 2023 | Aplenzin |
| Janssen Pharmaceuticals, INC | $183.67 | 2023-2024 | Invega Sustenna, Spravato |
| Almatica Pharma LLC | $148.18 | 2022-2025 | Loreev Xr, Sertraline Hcl |
| E.R. Squibb & Sons, L.L.C. | $143.55 | 2025 | Cobenfy |
| Indivior INC. | $134.87 | 2023 | Perseris, Sublocade |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $106.85 | 2022-2023 | Quviviq |
| Novo Nordisk INC | $105.68 | 2023 | Rybelsus, Ozempic |
| Supernus Pharmaceuticals, INC. | $105.66 | 2023-2025 | Qelbree, Qelbree |
| Neos Therapeutics, LP | $100.49 | 2023-2024 | Adzenys Xr-Odt |
| Tris Pharma INC | $64.76 | 2023 | Dyanavel Xr |
| Collegium Pharmaceutical, INC. | $47.89 | 2025 | Jornay Pm |
| Avion Pharmaceuticals | $44.24 | 2023 | Methylphenidate Hydrochloride |
| Neurocrine Biosciences, INC. | $36.53 | 2024 | Ingrezza |
| Vanda Pharmaceuticals INC. | $35.48 | 2025 | Fanapt, Hetlioz |
| Lilly USA, LLC | $13.44 | 2024 | Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Trisha Mayorga listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.